VTVT – vtv therapeutics inc. - class a (US:NASDAQ)
Stock Stats
News
VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst [Seeking Alpha]
vTv Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
vTv Therapeutics to Participate in Upcoming Investor Conferences
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
vTv Therapeutics (NASDAQ:VTVT) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock, up previously from $40.00.
Form 8-K vTv Therapeutics Inc. For: Feb 26
Form 4 vTv Therapeutics Inc. For: Feb 17 Filed by: SEKHRI PAUL J
Form 4 vTv Therapeutics Inc. For: Feb 17 Filed by: Tung Michael Stephen
Form 8-K vTv Therapeutics Inc. For: Jan 30
Form 8-K vTv Therapeutics Inc. For: Dec 19
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.